America Still Has Not Counted Its Thalidomide Survivors

US thalidomide survivors are asking the federal government to recognize them more than six decades after doctors gave the drug to pregnant patients in the 1950s and 1960s. Thalidomide did not have FDA approval, and patients were not always told they were receiving it. Their children were born with serious congenital injuries; those surviving children are now older adults seeking an official account that includes them.

The drug reached American patients through experimental distribution before approval. Surviving records establish that it circulated through physicians and clinics, but the paper trail does not identify every patient or every resulting birth injury. Medical files were lost, discarded, separated from families, or never created with informed consent in mind. The absence of a complete record is therefore part of the injury, not clean proof that exposure did not occur.

The victory and its missing people

The familiar American history presents thalidomide as a regulatory disaster avoided: the FDA withheld approval, the drug’s devastating effects became known, and stronger safeguards followed. That history contains a real institutional achievement. It is also too neat. Experimental use had already crossed the threshold into patients’ bodies before the country congratulated the gatekeeper.

A success story can preserve a reform while misplacing the harmed. In the polished version, the United States stands apart from countries where thalidomide caused a widely acknowledged catastrophe. Survivors disturb that civic memory because they show that refusal at the formal approval stage did not retrieve samples already distributed or restore consent that had never been obtained.

Recognition still requires standards. A confirmed exposure supported by a prescribing record is not identical to a plausible case reconstructed from maternal history, timing, and a characteristic pattern of injury. Yet a government-created process cannot demand documents the medical system failed to preserve and then call the resulting silence objective. Independent clinicians should apply published criteria, distinguish levels of evidence, and explain decisions in terms survivors can challenge.

A credible count now requires federal and corporate archives to be released, distribution records to be matched with surviving medical evidence, and rejected applicants to receive an appeals process. Recognition should also carry material consequences shaped by survivors’ present needs, including healthcare, assistive support, and the costs of aging with lifelong disabilities. The next official number should be treated not as a commemorative inscription but as an auditable beginning.